aspirin and clopidogrel stroke

), and Emmes, Rockville (A.S.L.)

It makes your blood flow through your veins more easily. A P value for interaction of less than 0.05 was considered to indicate statistical significance. Inset graphs show the same data on an expanded y axis.Race was determined by the investigator. Patients with ischemic stroke or transient ischemic attack carry a substantially higher risk of developing recurrent stroke and death than those without a previous stroke or transient ischemic attack.1 Results of prospective clinical trials and subsequent systematic reviews have established well‐accepted guidelines that antiplatelet agents are effective for secondary stroke prevention at both acute and chronic stages.7 Aspirin is the most widely prescribed antiplatelet agent as the … Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Information, resources, and support needed to approach rotations - and life as a resident.Valuable tools for building a rewarding career in health care.Information and tools for librarians about site license offerings.The authorized source of trusted medical research and education for the Chinese-language medical community.The most trusted, influential source of new medical knowledge and clinical best practices in the world.Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIAEnrollment and Outcomes (Intention-to-Treat Analysis).Discontinuation of a trial medication occurred in 29.6% of the patients in the group receiving clopidogrel plus aspirin and in 27.5% of those receiving aspirin alone; rates of withdrawal from the trial or loss to follow-up were 6.4% in the group receiving clopidogrel plus aspirin and 6.8% in the aspirin group.The composite primary efficacy outcome occurred in 121 patients (5.0%) receiving clopidogrel plus aspirin and in 160 patients (6.5%) receiving aspirin alone (hazard ratio, 0.75; 95% confidence interval [CI], 0.59 to 0.95; P=0.02) (Primary Efficacy Outcome, According to Predefined Subgroup.There were no significant treatment-by-subgroup interactions in prespecified subgroups, but the number of patients with available data for analysis limited the power to determine interactions (In a secondary analysis of the treatment effect according to time period, the benefit of clopidogrel plus aspirin was greater in the first 7 days and in the first 30 days than at 90 days (P=0.04 for days 0 to 7 and P=0.02 for days 0 to 30), whereas the risk of hemorrhage with clopidogrel plus aspirin versus aspirin alone was greater during the period from 8 to 90 days than during the first 7 days (P=0.04 for days 8 to 90 and P=0.34 for days 0 to 7) (Table S4 in the The primary safety outcome of major hemorrhage occurred in 23 of 2432 patients (0.9%) receiving clopidogrel plus aspirin and in 10 of 2449 patients (0.4%) receiving aspirin alone (hazard ratio, 2.32; 95% CI, 1.10 to 4.87; P=0.02) (Nonfatal, nonintracranial hemorrhage accounted for most of the major hemorrhages (16 in patients receiving clopidogrel plus aspirin and 7 in those receiving aspirin alone).Enrollment and Outcomes (Intention-to-Treat Analysis).Primary Efficacy Outcome, According to Predefined Subgroup. The NIHSS score was missing at baseline for 23 patients, and 6 patients had an NIHSS score above 3 and were excluded from the subgroup analysis of NIHSS score (score of 0 or 1 vs. score of 2 or 3). Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services.A complete list of the POINT Investigators is provided in the Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA).